Rituximab (Fa. Roche Pharma AG) Monoklonaler Antikörper. 15. 6. 2010; MSIF; Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: A 52-week phase II trial http://www.msif.org/en/research/ms_research_news/rituximab_addon.html 28. 6. 2010; PublMed.gov; Changes in B- and T-lymphocyte and chemokine levels with rituximab treatment in multiple sclerosis. http://www.ncbi.nlm.nih.gov/pubmed/20558389 15. 12. 2010; PubMed.gov; Antibodies against CD20 (rituximab) for treating multiple sclerosis: US20100233121. http://www.ncbi.nlm.nih.gov/pubmed/21155688 „Conclusion. Antibodies against CD20 and rituximab offer new opportunities to treat patients with MS.“ 19. 1. 2011; PubMed.gov; Rituximab dosing and monitoring strategies in neuromyelitis optica patients: creating strategies for therapeutic success. http://www.ncbi.nlm.nih.gov/pubmed/22261118 "Conclusions: Low doses of rituximab have a high rate of early B-cell repopulation. Any NMO patient treated with rituximab should be followed with monthly CD19 counts in order to identify the rare, but clinically significant, early repopulators." Feb. 2011; PubMed.gov; Incidence of Infusion-Associated Reactions with Rituximab for Treating Multiple Sclerosis: A Retrospective Analysis of Patients Treated at a US Centre. http://www.ncbi.nlm.nih.gov/pubmed/21247220 „Conclusions: The occurrence of infusion-associated reactions to rituximab in patients with MS is fairly common. However, premedication that includes corticosteroids may reduce the incidence of reactions dramatically. Should they occur, proper treatment of reactions with histamine H(1) or H(2) receptor antagonists and infusion rate reduction is an effective management strategy in this situation.“ 1. 2. 2011; PubMed.gov; Incidence of Infusion-Associated Reactions with Rituximab for Treating Multiple Sclerosis: A Retrospective Analysis of Patients Treated at a US Centre. http://www.ncbi.nlm.nih.gov/pubmed/21247220 „Conclusions: The occurrence of infusion-associated reactions to rituximab in patients with MS is fairly common. However, premedication that includes corticosteroids may reduce the incidence of reactions dramatically. Should they occur, proper treatment of reactions with histamine H(1) or H(2) receptor antagonists and infusion rate reduction is an effective management strategy in this situation“ Julv 2011; PubMed.gov; Rituximab for secondary progressive multiple sclerosis: a case series. http://www.ncbi.nlm.nih.gov/pubmed/21699272 „Results: During the observation period, no severe adverse effects occurred and the Expanded Disability Status Scale (EDSS) score stabilized in all patients after a dramatic increase over the previous years.“ 18. 4. 2013; amsel.de; Rote-Hand-Brief zu Rituximab http://www.amsel.de/multiple-sklerose-news/medizin/Rote-Hand-Brief-zu-Rituximab_4780 2. 7. 2013; PubMed.gov; Rituximab in Relapsing and Progressive Forms of Multiple Sclerosis: A Systematic Review. http://www.ncbi.nlm.nih.gov/pubmed/23843952 26. 9. 2013; aerzteblatt.de; Tödliche Hepatitis B unter Rituximab und Ofatumumab http://www.aerzteblatt.de/nachrichten/55993 27. 9. 2013; amsel.de; Hepatitis-B unter Rituximab und Ofatumumab http://www.amsel.de/multiple-sklerose-news/medizin/Hepatitis-B-unter-Rituximab-und-Ofatumumab_4908 8. 3. 2016; ns-uk; Progressive MS trial of Rituximab is stopped (08/03/16) http://www.ms-uk.org/mar6 4. 12. 2017; Aktiv mit MS: Video: Vitamin D bei Multipler Sklerose https://www.aktiv-mit-ms.de/leben/artikel/video-vitamin-d-bei-multipler- sklerose/?utm_medium=email&utm_source=newsletter&utm_campaign=de_2017_41_de%7Cpatient%7Cnewsletter_aktiv_mit_ms _patient_dezember_de&utm_content=website&utm_sender=teva&utm_id=8146 „Wer fragt, der führt.“ Davul Ljuhar Zur Medikamenten-Übersicht